Chief Financial Officer
James brings more than two decades of experience across corporate finance, capital markets and strategic advisory. Prior to joining RxLogix, James was chief financial officer of Bluebird Bio, a publicly-traded gene therapy pioneer with three commercial FDA-approved therapies for severe genetic disorders.
Before Bluebird, James served as chief financial officer of Renalytix plc, a diagnostics company focused on kidney disease, where he helped guide the company through clinical and commercial development, and led the company’s initial public offerings in the UK and on Nasdaq.
Prior experience includes leadership roles in investment banking and finance advisory, and as a management consultant earlier in his career with the corporate strategy division of Booz Allen Hamilton (now known as Strategy& and part of PwC).
James serves on the board of Star Mountain Lower Middle-Market Capital Corp., where he chairs the audit committee. He holds an MBA from Columbia Business School and a B.A. from Boston University.
RxLogix provides the industry's best solutions to the ever-changing drug safety & pharmacovigilance
BOOK A DEMOSubscribe to our newsletter and learn the latest news from RxLogix.
Information on RxLogix Products – info@rxlogix.com
RFI and RFP Response Request – sales@rxlogix.com
Sales Inquiries – sales@rxlogix.com
Marketing Inquiries – marketing@rxlogix.com
Career Opportunities – careers@rxlogix.com
